Update on Aimmune Therapeutics Versus DBV Technologies Peanut Allergy-Related Candidate Treatments


Summary:

  • DBVT’s peanut allergy-related therapy recently failed its efficacy endpoint in a Phase 3 clinical trial.

  • DBVT lost about 50% of its value, but still appears to be over-valued.

  • AIMT gained about 40% of its value and appears close to fully valued for upcoming Phase 3 success.

UPDATED INVESTMENT THESIS:

We previously published a Seeking Alpha article where we concluded that although AIMT appeared to have a more efficacious treatment for preventing severe anaphylaxis upon accidental exposure to peanuts, both AIMT and DBVT would eventually be commercially successful for their therapies. We recommended taking a small position in both companies, noting that the prices had already run up earlier this year ahead of their Phase 3 readouts this fall (DBVT) and early next year (AIMT). Since our article published, DBVT reported that it’s efficacy trial did not meet its FDA-agreed end-point. As a result, since our article published DBVT has lost almost 50% of its market value ($2.3B to $1.2B) and AIMT’s market cap has increased almost 40% ($1.3B to $1.8B). However, while AIMT’s current valuation can be justified, we feel that even after...

Read the rest of our article here.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon